Back

Phosphodiesterase 9A - novel biomarker or potential therapeutic target in patients with heart failure and preserved ejection fraction?

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Rapid Fire 2 - Biomarker: present and future Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Karl-Philipp Rommel

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)

10 More presentations in this session

Presentation thumbnail
Role of neprilysin in myocardial tissue Renin-Angiotensin-System (RAS) of the failing heart
Doctor N. Pavo (Vienna, AT)
Abstract
Presentation thumbnail
The value of tubular maximum phosphate reabsorption capacity, a functional proximal tubular parameter in heart failure
Ms L. Emmens (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
The risk of bias of current novel circulating biomarker studies for the detection of HFpEF and left ventricular diastolic dysfunction
Mr M. Henkens (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients
Doctor R. Nielsen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Improvement of existing strategies to prevent heart failure after myocardial infarction: a potential role for thrombopoietin
Associate Professor L. Malinova (Saratov, RU)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire 2 - Biomarker: present and future

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources